Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201–26. https://doi.org/10.1007/s40273-018-0734-2.

Article  PubMed  Google Scholar 

Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883–902. https://doi.org/10.1007/s40273-014-0170-x.

Article  PubMed  Google Scholar 

Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R, et al. A systematic review of discrete choice experiments in oncology treatments. Patient. 2021;14:775–90. https://doi.org/10.1007/s40271-021-00520-4.

Article  PubMed  Google Scholar 

Vass C, Boeri M, Karim S, Marshall D, Craig B, Ho KA, et al. Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR special interest group report. Value Health. 2022;25(5):685–94. https://doi.org/10.1016/j.jval.2022.01.012.

Article  PubMed  Google Scholar 

Roudijk B, Donders ART, Stalmeier PFM. Cultural values: can they explain differences in health utilities between countries? Med Decis Making. 2019;39(5):605–16. https://doi.org/10.1177/0272989x19841587.

Article  PubMed Central  PubMed  Google Scholar 

Pharmaprojects, a drug development database. Pharma Intelligence. 2020. https://pharmaintelligence.informa.com/products-and-services/clinical-planning/pharmaprojects. Accessed March 1, 2023.

Estimates of cancer incidence and mortality in 2020, for all cancer sites. European Cancer Information System. https://ecis.jrc.ec.europa.eu/index.php. Accessed March 1, 2023.

Bilim V, Kuroki H, Shirono Y, Murata M, Hiruma K, Tomita Y. Advanced bladder cancer: changing the treatment landscape. J Pers Med. 2022;12(10):1745. https://doi.org/10.3390/jpm12101745.

Article  PubMed Central  PubMed  Google Scholar 

Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404–23. https://doi.org/10.3322/caac.21631.

Article  PubMed  Google Scholar 

European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-bavencior-avelumab-first-line. Accessed March 1, 2023.

Powles T, Bellmunt J, Comperat E, M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.11.01.

Article  PubMed  Google Scholar 

Witjes J, Compérat E, Cowan N, De Santis M, Gakis G, James N, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. European Association of Urology. 2022. ISBN 978-94-92671-16-5. http://uroweb.org/guidelines/compilations-of-all-guidelines/. Accessed March 1, 2023.

Grivas P, Veeranki P, Chiu K, Pawar V, Chang J, Bharmal M. Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients. Future Oncol. 2023;19(5):369–83. https://doi.org/10.2217/fon-2022-0767.

Article  CAS  PubMed  Google Scholar 

Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–15. https://doi.org/10.1016/j.jval.2016.04.004.

Article  PubMed  Google Scholar 

Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–13. https://doi.org/10.1016/j.jval.2010.11.013.

Article  PubMed  Google Scholar 

Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. https://doi.org/10.1016/j.jval.2012.08.2223.

Article  CAS  PubMed  Google Scholar 

Balar AV, Apolo AB, Ostrovnaya I, Mironov S, Iasonos A, Trout A, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013;31(6):724–30. https://doi.org/10.1200/JCO.2012.42.5215.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–92. https://doi.org/10.1016/S1470-2045(17)30616-2.

Article  CAS  PubMed  Google Scholar 

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. https://doi.org/10.1016/S0140-6736(16)32455-2.

Article  CAS  PubMed  Google Scholar 

Galsky MD, Arija JAA, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547–57. https://doi.org/10.1016/S0140-6736(20)30230-0.

Article  CAS  PubMed  Google Scholar 

Galsky MD, Powles T, Li S, Hennicken D, Sonpavde G. A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901). J Clin Oncol. 2018;36(6_suppl):TPS539. https://doi.org/10.1200/JCO.2018.36.6_suppl.TPS539.

Article  Google Scholar 

Galsky MD, Necchi A, Sridhar SS, Ogawa O, Angra N, Hois S, et al. A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE). J Clin Oncol. 2021;39(6_suppl):TPS504. https://doi.org/10.1200/JCO.2021.39.6_suppl.TPS504.

Article  Google Scholar 

Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol. 2020;38(16):1797–806. https://doi.org/10.1200/JCO.19.03091.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SYS, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931–45. https://doi.org/10.1016/s1470-2045(21)00152-2.

Article  CAS  PubMed  Google Scholar 

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788.

Article  CAS  PubMed  Google Scholar 

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574–88. https://doi.org/10.1016/S1470-2045(20)30541-6.

Article  CAS  PubMed  Google Scholar 

De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9. https://doi.org/10.1200/JCO.2011.37.3571.

Article  CAS  PubMed  Google Scholar 

van der Heijden MS, Gupta S, Galsky MD, Derleth C, Steinberg J, Kataria R, et al. 798TiP Study EV-302: a 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer. Ann Oncol. 2020;31:S605–6. https://doi.org/10.1016/j.annonc.2020.08.2069.

Article  Google Scholar 

Vuky J, Balar AV, Castellano D, O’Donnell PH, Grivas P, Bellmunt J, et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2020;38(23):2658–66. https://doi.org/10.1200/JCO.19.01213.

Article  CAS  PubMed  Google Scholar 

Bin Riaz I, Khan AM, Catto JW, Hussain SA. Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. Expert Opin Investig Drugs. 2021;30(8):837–55. https://doi.org/10.1080/13543784.2021.1948999.

Article  CAS  PubMed  Google Scholar 

Powles T, Petrylak DP, Park SH, Sridhar SS, Caserta C, Vuillemin AT, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial. J Clin Oncol. 2021;39(15_suppl):4520. https://doi.org/10.1200/JCO.2021.39.15_suppl.4520.

Article  Google Scholar 

Milloy N, Kirker M, Unsworth M, Montgomery R, Kluth C, Kearney M, et al. Real-world analysis of treatment patterns and platinum-based treatment eligibility of patients with metastatic urothelial cancer in 5 European countries. Clin Genitourin Cancer. 2023. https://doi.org/10.1016/j.clgc.2023.09.010.

Article  PubMed  Google Scholar 

Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge: Cambridge University Press; 2000.

Book  Google Scholar 

Bröckelmann PJ, McMullen S, Wilson JB, Mueller K, Goring S, Stamatoullas A, et al. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol. 2019;184(2):202–14. https://doi.org/10.1111/bjh.15566.

Article  PubMed  Google Scholar 

Qian Y, Arellano J, Gatta F, Hechmati G, Hauber AB, Mohamed AF, et al. Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom. BMC Health Serv Res. 2018;18(1):1–10. https://doi.org/10.1186/s12913-018-3272-x.

Article  Google Scholar 

Wheeler B. AlgDesign. the R project for statistical computing https://www.r-projectorg/. Accessed October 1, 2022.

Aizaki H, Nishimura K. Design and analysis of choice experiments using R: a brief introduction. Agric Inf Res. 2008;17(2):86–94.